PRF1 and neoplasm: Following priming, these cells can then become activated either in the lymphoid organs or peripheral tissues when antigenic epitopes released by a tumor bind the T cell receptor (TCR) and CD28 co-stimulation occurs, allowing for these cells to traffic to the site of the tumor and release granzymes and perforins.